Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q2 2023 call → NOWe need to determine if the transcript describes a situation where the company is currently living through a defined waiting period it is paying for out of its own pocket, with a specific near-dated event that ends the wait, and the cost is real and currently landing in results. Let's analyze the transcript. Key points: - The company has a strong first half, revenue growth, etc. - They mention a $60 million financing from FIMI, expected to close later this quarter (Q3 2023). That is a future event, but it's about financing, not a waiting period for a business operation. - They discuss KEDRAB sales, which are already generating revenue. - They discuss the InnovAATe clinical trial for Inhaled Alpha-1 Antitrypsin. Enrollment is ramping, 62 patients out of ~220. This is a development program, but it's not described as a waiting period where they are paying costs now for something not yet earning. They are spending on R&D, but that's normal for a biotech. The trial is ongoing, and they expect to complete discussions with FDA by end of year. But the trial itself is not a defined waiting period with a specific near-dated event that will bring revenue. The trial is a long-term investment. - They mention the tech transfer of CYTOGAM to their Israeli facility. They received FDA approval in May, and Health Canada approval recently. They expect to initiate sales of product manufactured in Israeli facility early in Q4 2023. This is a specific event: they have been paying for the tech transfer, and now they will start selling product from that facility. This could be a waiting period: they incurred costs for the transfer, and now they will start earning. But is it described as a current cost? They say "This approval ensure continued supply of CYTOGAM to the U.S. and the Canadian markets with no interruptions, and we expect to initiate sell of the product manufactured in our Israeli facility early in the fourth quarter of this year." So they have been paying for the tech transfer, and now they will start selling. But is that a major cost? They don't quantify it. Also, they already have revenue from CYTOGAM from the previous manufacturer. So it's not a new product, just a new manufacturing site. The benefit is continued supply, not new revenue. So it's not a waiting period for a new earning stream.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.